Celltrion announced the US commercial availability of OMLYCLO on October 5, 2026, introducing a new option for eligible patients. The treatment is an interchangeable biosimilar referencing Xolair, an established biologic medicine targeting immunoglobulin E. The OMLYCLO Biosimilar launch marks an important commercial development across allergy and immunology care, extending an existing regulatory milestone into market availability.
OMLYCLO Biosimilar Brings Competition to Established Biologic Care
The product was previously approved by the US Food and Drug Administration in March 2025. Its commercial availability now gives eligible patients and healthcare providers another option within an established treatment category. The OMLYCLO Biosimilar is approved for four indications: moderate-to-severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria. These conditions affect different patient populations, making the launch relevant across several areas of clinical practice.
Celltrion says the product is available in single-dose prefilled syringes containing 75 mg, 150 mg, and 300 mg. The interchangeable designation may support substitution under applicable US regulations and state pharmacy laws. Actual substitution requirements depend on local rules and the specific prescription. The OMLYCLO Biosimilar therefore introduces a commercial alternative without requiring patients to assume that every treatment circumstance is interchangeable.
For patients, the launch could broaden treatment choice, although affordability will depend on pricing, insurance coverage, and access arrangements. Biosimilar competition can create pressure for better value, but lower patient costs are not guaranteed. Providers and payers will need to assess product availability, reimbursement, prescribing requirements, and suitability for individual patients. The OMLYCLO Biosimilar also enters a market where treatment decisions depend on clinical history and condition-specific guidance.
The product is not intended for emergency treatment of anaphylaxis or acute asthma attacks. Omalizumab products also carry a serious warning concerning anaphylaxis, which can occur after treatment begins. Patients should follow their healthcare professional’s instructions and the approved prescribing information. The OMLYCLO Biosimilar launch is consequently a meaningful market development, but treatment suitability and safety remain central to prescribing decisions.
